Worldwide survey among polyposis registries of surgical management of severe duodenal adenomatosis in familial adenomatous polyposis. BJS 2003; 90: 705-710.
Published: 25th February 2003
Authors: W. H. de Vos tot Nederveen Cappel, H. J. Järvinen, J. Björk, T. Berk, G. Griffioen, H. F. A. Vasen et al.
The lifetime risk of developing duodenal cancer in familial adenomatous polyposis (FAP) is about 5 per cent. When and to what extent surgical intervention should be undertaken to prevent death from invasive carcinoma is controversial. The aim of this study was to determine the effectiveness of various surgical treatments for cancer and severe duodenal adenomatosis.
A questionnaire was mailed to the members of the Leeds Castle Polyposis Group to obtain data on patients with FAP, treated for duodenal cancer or severe duodenal adenomatosis after 1990.
Sixty‐nine patients were included. The indication for surgery was invasive cancer in 13 patients, of whom six died from metastatic disease. Fifty‐six patients were initially treated for severe duodenal adenomatosis, five (9 per cent) of whom died from metastatic disease (P = 0·002). In surviving patients, adenomas recurred after ampullectomy (six of eight, at mean follow‐up of 11 months), after duodenotomy with polypectomy (17 of 21, at mean 29 months) and after pancreatoduodenectomy (six of 25, at mean 47 months). None of six patients who underwent a pancreas‐sparing duodenectomy had recurrence of adenoma (mean follow‐up 11 months).
Surgery for duodenal adenomatosis should take place before endoscopic biopsy reveals invasive cancer. Even after extensive surgical procedures, small bowel adenomas may occur, emphasizing the need for chemoprevention. Copyright © 2003 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.Full text